Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Excel PharmaStudies Chairman Mark Engel On China’s Rapidly Expanding Clinical Trials: An Interview With PharmAsia News (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Excel PharmaStudies, established in 2000, is one of the leading clinical research organizations in China. Excel PharmaStudies Chairman Mark Engel recently talked with PharmAsia News' Beijing bureau about the high-speed development of China's pharmaceutical market and the role of clinical trials in China. Engel also outlined challenges, solutions and opportunities regarding clinical trials in China.
Advertisement

Related Content

PPD Continues High-speed Expansion In Asia With Second Acquisition Of A China-based CRO This Quarter
PPD Continues High-speed Expansion In Asia With Second Acquisition Of A China-based CRO This Quarter
PPD Continues High-speed Expansion In Asia
PPD Continues High-speed Expansion In Asia
PPD Acquires China-based CRO Excel To Continue Global Expansion
PPD Acquires China-based CRO Excel To Continue Global Expansion
CROs in Asian Giants India and China Create Alliance To Conduct Clinical Trials To Keep Pace With Exploding Demand
Excel PharmaStudies Chairman Mark Engel On China’s Rapidly Expanding Clinical Trials:  An Interview With PharmAsia News (Part 2 of 2)
Import Safety Agreement Further Entwines FDA/China Regulatory Process
Import Safety Agreement Further Entwines FDA/China Regulatory Process
Advertisement
UsernamePublicRestriction

Register

SC068856

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel